Author:
Yndestad Synnøve,Austreid Eilin,Knappskog Stian,Chrisanthar Ranjan,Lilleng Peer Kåre,Lønning Per Eystein,Eikesdal Hans Petter
Funder
Helse Vest
Bergens Forskningsstiftelse
Kreftforeningen
Rieber Foundation
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Eikesdal HP, Knappskog S, Aas T, Lonning PE (2014) TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncol 53:1–9. doi: 10.3109/0284186X.2014.922215
2. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811–814
3. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582–5588
4. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505–2512
5. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjonsberg G, Aas T, Schlichting E, Fjosne HE, Nysted A, Lillehaug JR, Lonning PE (2011) Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS ONE 6:e19249. doi: 10.1371/journal.pone.0019249
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献